EMD Millipore and Samsung BioLogics signed a Memorandum of Understanding (MOU) for a strategic alliance to encompass a long-term supply agreement in which EMD Millipore will provide raw materials for biopharmaceutical manufacturing.

“Our latest partnership in the biopharmaceutical sector will further strengthen the great relationship built in other business areas for the past years. It will also help us support Samsung’s initiative in the CMO and biopharmaceutical field,” said Udit Batra, Ph.D., president and CEO of EMD Millipore.

EMD Millipore will become an essential raw material supplier for Samsung BioLogics’ 30 KL facility as well as its new 150 KL facility that is expected to be completed in 2015 at Songdo, Incheon, Korea.








This site uses Akismet to reduce spam. Learn how your comment data is processed.